Neurosky, Inc.

Neurosky, Inc. designs and develops advanced biosensor technologies, specializing in electroencephalogram (EEG) and electrocardiogram (ECG) solutions that enhance consumer health and wellness monitoring. Founded in 2004 by Jongjin Lim and KooHyoung Lee, Neurosky, Inc. is headquartered in San Jose, US.

The company focuses on the development of biosensor technologies and has undergone a strategic evolution to cater to the consumer wearable market. In a notable funding round, Neurosky secured USD 11. 8 mn in Series C funding from investors including Hambrecht Capital and Marubeni, contributing to a total raised amount of USD 11. 8 mn.

The latest deal occurred on November 4, 2013. NeuroSky specializes in advanced biosensor technologies, particularly focusing on electroencephalogram (EEG) and electrocardiogram (ECG) biosensors. Their core product offerings include the Cardiochip™, a compact ECG biosensor, and a variety of EEG biosensors designed for consumer-level brainwave monitoring. These products aim to provide users with insights into their health and wellness by capturing and analyzing biometric data, allowing for applications such as stress and anxiety management, fitness tracking, and mood evaluation.

The primary end users are children and adults interested in health and wellness, as well as organizations developing next-generation wearable technology. NeuroSky's products cater to various geographical markets, including North America, Europe, and parts of Asia, enabling widespread adoption across diverse consumer bases and enhancing the functionalities of partner devices. NeuroSky generates revenue through a combination of direct sales and partnerships with developers and manufacturers of consumer wearable devices. Their business model involves supplying advanced biosensor technologies and providing associated services to original equipment manufacturers (OEMs) and original design manufacturers (ODMs).

Transaction structures typically include B2B arrangements where clients procure biosensor components and biometric algorithms for integration into their products. Notable flagship offerings, such as the Cardiochip™, serve as key components in the mHealth solutions that partners offer to end consumers. Specific pricing plans are structured around the nature of partnerships and bulk orders, facilitating a scalable approach to market entry for clients across various industries within the health and wellness sector. Neurosky plans to utilize recent funding to enhance product development and expand its market reach.

They are focused on launching new biosensor products tailored for emerging health technology applications within the next two years. Furthermore, the company aims to penetrate additional geographic markets, specifically targeting regions in Asia and Europe by 2015. The funding received in November 2013 will support these initiatives, enabling the company to develop innovative solutions and strengthen its partnerships with OEMs and ODMs.